Quantitative analysis for Filana Therapeutics, Inc. (FLNA) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (26.0) (grade F). 29 signals analyzed (25 differentiated alt-data).
FLNA stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $1.56 | $1.43 | $1.44 |
| 2026-05-11 | $1.35 | $1.28 | $1.28 |
| 2026-05-21 | $1.30 | $1.22 | $1.29 |
| 2026-06-03 | $1.45 | $1.35 | $1.36 |
| 2026-06-15 | $1.29 | $1.17 | $1.21 |
| 2026-06-26 | $1.21 | $1.15 | $1.20 |
| 2026-07-09 | $1.23 | $1.16 | $1.19 |
| 2026-07-21 | $1.03 | $1.00 | $1.01 |
| 2026-07-31 | $1.02 | $0.94 | $1.01 |
| 2026-08-12 | $0.98 | $0.92 | $0.93 |
| 2026-08-24 | $0.95 | $0.92 | $0.93 |
| 2026-09-03 | $0.89 | $0.82 | $0.83 |
How Filana Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | $61M | — |
| BGM | BGM Group Ltd. | $59M | — |
| PDSB | PDS Biotechnology Corporation | $57M | — |
| CBUS | Cibus, Inc. | $65M | — |
View all Health Care stocks by valuation and signals →
Filana Therapeutics, Inc. (FLNA) scores Strong Sell (26.0), and the composite conceals a 70-point disagreement between its dimensions. It is strongest on valuation at 72, and weakest on competitive moat at 4 and technicals at 2. A stock can carry valuation that high while technicals sits at 2; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| valuation | 72 |
| earnings quality | 51 |
| competitive moat | 4 |
| technicals | 2 |
StoQuant analyzes 29 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Filana Therapeutics, Inc. (FLNA): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/FLNA"><img src="https://stoquant.com/badge/FLNA.svg" alt="Filana Therapeutics, Inc. (FLNA) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.